# Predoctoral Training Grant in Pharmacology INCLUDE Down Syndrome Supplement

> **NIH NIH T32** · UNIVERSITY OF COLORADO DENVER · 2020 · $110,288

## Abstract

Abstract:
 The University of Colorado Anschutz Medical Campus (UC/AMC) Pharmacology Graduate Training
Program is currently in its 41st year of NIGMS funding. The Training Program distinguishes itself by providing a
highly interactive environment in which students obtain a broadly-based integrative perspective on science and
training in the fundamental knowledge defining pharmacology. The Principle Investigator for the Training Grant
is Dr. Mark Dell'Acqua, Vice Chair of the Department of Pharmacology. The Training Program Director and co-
PI of the Training Grant is Dr. David Port, who Chairs the Graduate Training Committee (GTC), which provides
the day-to-day oversight for this Training Program. The ~50 members of the Training Program faculty are
drawn from numerous departments within the School of Medicine and have been recruited to provide broad,
multidisciplinary training opportunities in neuropharmacology, cell signaling, pharmacogenetics, cancer biology,
cardiovascular/pulmonary biology, molecular structure, and bioinformatics. Training Program faculty are all
accomplished, committed researchers and mentors with significant extramural funding. The sources of
students entering the Training Program include direct applicants to the Program, as well as students who
transition from `umbrella' programs (Biomedical Sciences and Medical Scientist Training Programs). Hallmarks
of the Program are a comprehensive didactic component, 3 laboratory rotations, a strong emphasis on student
presentations in seminar settings, and a wide choice of thesis research options. Career development in the
pharmacological sciences and student initiative are also emphasized. The Training Program currently has a
total of 33 students including 7 students from the MSTP track. The competitiveness of the students for
individual national fellowships, high quality publications in peer-reviewed journals and invitations to participate
in national meetings are all measures by which the successful training of the students is gauged. Retention of
the graduates in academic, industry and government positions is another measure of the success of the
Training Program. The Program continues to thrive and meet the national demands for individuals, trained as
pharmacologists, who are individually astute researchers, can be multidisciplinary research team members,
and also have the breadth of knowledge to plan and communicate effectively across a spectrum of
technologies.
 The current proposal for a renewal of an INCLUDE Down syndrome supplement to the existing parent
Program that will serve to continue to enhance the already robust environment for training graduate students in
areas of scientific enquiry germane to Down syndrome and its co-occuring conditions. As articulated in the
proposal, a number of faculty mentors in the training program are deeply invested in Down syndrome related
research and are actively engaged in training mentees in this area.

## Key facts

- **NIH application ID:** 10130360
- **Project number:** 3T32GM007635-42S1
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** MARK L DELL'ACQUA
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $110,288
- **Award type:** 3
- **Project period:** 1978-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10130360

## Citation

> US National Institutes of Health, RePORTER application 10130360, Predoctoral Training Grant in Pharmacology INCLUDE Down Syndrome Supplement (3T32GM007635-42S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10130360. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*